NPC1L1 and familial hypercholesterolemia: Among the options to successfully lower atherogenic blood lipids are therapeutics against drug targets that when mutated cause familial hypercholesterolemia (FH), such as NPC1L1, the target of ezetimibe, or PCSK99.